Background: A biomarker test based on a combination of urine tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) has been used as a potential biomarker of acute kidney injury (AKI). This meta-analysis aimed to evaluate the predictive value of this biomarker for cardiac surgery-associated acute kidney injury (CSA-AKI). Methods: We searched MEDLINE, PubMed, Cochrane, and EMBASE for studies. We evaluated the methodological quality of each included study using the Quality Assessment of Diagnostic Accuracy Studies 2 criteria. Meta-DiSc and STATA were used for statistical analyses. Results: A total of 10 studies (747 patients) were included in this meta-analysis. Pooled sensitivity and specificity with corresponding 95% confidence intervals (CI) were 0.77 (95% CI: 0.70e0.83, I
is essential for early implementation of strategies to prevent the development of severe kidney damage. Therefore, it is of great importance to find potential markers exhibiting acceptable accuracy for early diagnosis of kidney injury after cardiac surgery. A biomarker test based on a combination of urine tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) was recently approved by the US Food and Drug Administration for AKI risk stratification. 6 TIMP-2 and IGFBP7 have been linked to cell-cycle arrest, which is known to be involved in the pathogenesis of AKI. 7 Several studies have reported that 
Study selection
Two investigators independently conducted the study selection. Any disagreement was resolved by consultation with a third investigator. Studies included met the following criteria:
(1) original study; (2) patients undergoing cardiovascular surgery; (3) urinary [TIMP-2]$[IGFBP7] as biomarkers for CSA-AKI diagnosis; and (4) sufficient information to calculate SEN and specificity (SPE). Exclusion criteria were as follows: (1) studies from conference abstracts, guidelines, letters, editorials, or reviews; and (2) studies without sufficient data for analysis, even after contacting the authors.
Data extraction and quality assessment
Data on patient and study characteristics were collected and entered into a database for assessment of study eligibility. If eligible, we extracted relevant data, using a standardised data extraction form. The following information was extracted from each study: first author, publication data, study design, patient setting, age, sample size, test method, timing at measurement, AKI definition, true positive rate, false positive rate, false negative rate, true negative rate, SEN, SPE, and area under the curve (AUC). We assessed the methodologic quality by using the Quality Assessment of Diagnostic Accuracy Studies (QUA-DAS-2) tool. 20 Both data extraction and quality assessment were performed independently by two reviewers and discussed with a third assessor when discrepancies were present.
Statistical analysis
Meta-DiSc 1.4 software (Zamora J, Muriels A, Abraira V, Madrid, Spain) was used for statistical analysis. A randomeffects model (DerSimonian and Laird method) or fixedeffects model (MantelÀHaenszel method) was constructed to estimate pooled SEN, SPE, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) with 95% confidence intervals (CI). Model selection was based on the heterogeneity of included studies. 21 The analysis of diagnostic accuracy accords with summary receiver operating characteristics (SROC) curve and the AUC of the SROC. Heterogeneity induced by the threshold effect was reflected by a 
Results
Eligible studies and study characteristics
After our search, a total of 105 articles were initially identified. We excluded 89 articles that were not relevant to our topic or duplicates. Full-text reviews were performed on 16 potentially eligible articles. Two studies were excluded because of insufficient data for analysis, 24, 25 and a third for including patients not receiving cardiac surgery. 26 We also excluded three review articles. 7, 27, 28 Ultimately, 10 prospective cohort studies (747 patients) were selected ( Fig. 1) . Details on the studies are shown in Tables 1 and 2 .
Quality assessment of studies
On the basis of QUADAS-2, quality outcomes are shown in Figure 2 . The QUADAS-2 scores indicated that the quality of the included studies was generally good. Our results revealed that some studies had a high risk in the index test because these studies had not used a setting threshold. 8e12 Regarding the reference standard, two studies were evaluated as unclear risk because they did not mention blinding. None of the studies had a concern for applicability. 
Predictive accuracy

Threshold effect and heterogeneity analysis
The primary source of heterogeneity is the threshold effect, as different studies used different cut-off values to define positive and negative test results. If a threshold effect exists, the ROC plane scatter distribution is in a typical 'shoulder arm-shaped' style, and the SEN would show a negative correlation to the SPE. 22 In our analysis, the SROC curve did not show this typical style (Fig. 3) , and the Spearman correlation coefficient between SEN and the false-positive rate was À0.389 (P¼0.266), indicating a lack of a threshold effect. We also used DOR to explore heterogeneity caused by nonthreshold effects. There was low heterogeneity among the 10 studies on the basis of the Q test (P¼0.29) and Higgins heterogeneity statistic test (I 2 ¼16.5%). 
Publication bias
Deeks' funnel plot asymmetry test was used to evaluate publication bias. The finding of P¼0.08 suggests that likelihood of publication bias is low (shown in Fig. 2 ).
Subgroup analysis
To further investigate the value of [TIMP-2]$[IGFBP7] for diagnosis of CSA-AKI among different ages, diagnostic criteria, and timing of measurement, we performed a series of subgroup analyses. As two of the 10 studies enrolled infants, we reanalysed the data on adults only. SEN and SPE of the adult subgroup were almost the same as the summary outcomes (0.76 and 0.77, respectively). The AUC for this subgroup was 0.84. There were seven studies that used all stages of kidney disease: improving global outcomes (KDIGO)/paediatric risk, injury, failure, loss, end-stage renal disease (pRIFLE) as AKI diagnosis criteria and three studies adopted Stage 2e3 KDIGO ¼29.5%). The details of the various subgroup analyses results are presented in Table 3 .
Discussion
Current diagnosis of AKI is based on serum creatinine and urine output, yet their diagnoses were proved to be insensitive especially for early detection. 29 Thus, it emphasises the importance of novel biomarkers for early prediction of AKI. However, a previous meta-analysis demonstrated that several biomarkers including plasma and urine neutrophil gelatinaseassociated lipocalin, urinary liver-type fatty acid-binding proteins, and urinary kidney injury molecule-1 had relatively low diagnostic accuracy (AUC<0.75) for CSA-AKI. 30e33 We performed this meta-analysis and identified 10 studies (747 patients) reporting diagnostic value of urinary [TIMP-2]$ [IGFBP7] for CSA-AKI. Overall, we found that this biomarker test has good diagnostic accuracy (AUC¼0.83, SEN¼0.77, SPE¼0.76).
There was little heterogeneity among the 10 studies from both threshold and non-threshold effects suggesting that the results of our meta-analysis are unlikely to be biased by a small number of studies. Our results are in line with a previous meta-analysis not limited to CSA-AKI (including only 203 cardiac surgery patients).
14 To our knowledge, this is the first meta-analysis to evaluate the predictive value of urinary [TIMP-2]$[IGFBP7] specifically for CSA-AKI. Not surprisingly, test characteristics were optimal for KDIGO Stage 2e3 AKI because some KDIGO Stage 1 AKI were probably purely functional with no actual damage to the kidney. Indeed, in large studies controlling for severity of illness, KDIGO Stage 1 AKI is not associated with decreased survival or risk for dialysis. 2 Interestingly, studies that assessed the outcome over 24 h after operation showed improved accuracy compared with those using 12 h. This result may have occurred because the biomarkers were measured during or immediately after surgery, whereas in the discovery studies, patients were enrolled up to 24 h after ICU admission. 34, 35 Our study also has some important limitations. First, the studies we included did not all use the same protocol and end points varied across studies. Two studies were excluded for lack of sufficient data. 24, 25 Thus, there may have been outcome reporting bias. Second, as a gold standard for diagnosing AKI by KDIGO, serum creatinine is affected by age, diet, muscle mass, drugs, creatinine volume of distribution, and delayed response to injury. 13 Third, we only focused on the predictive value of the biomarker on AKI (within 7 days); however, acute kidney disease (7e90 days) and chronic kidney disease (>90 days) form a continuum that includes AKI. 42 We could not explore these endpoints because of limited reporting in the primary studies. Fourth, the differences of cut-off values, the differences among AKI severity, and differences between adults and paediatric patients would be expected to affect the diagnostic accuracy. Sub-group analyses to address these questions were not possible because of the limited numbers of studies. Lastly, RRT, an important parameter for CSA-AKI progression, could not be directly explored in this analysis because of limited events. Additional, high-quality studies examining some of these subgroup analyses and examining the effect of implementation of biomarker-guided therapy are indicated.
Conclusion
Our meta-analysis suggests that the urinary [TIMP-2]$[IGFBP7] is an effective predictive marker for CSA-AKI with good accuracy within 24 h of surgery. 
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